Results 1 to 10 of about 118,861 (266)

Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study. [PDF]

Lancet HIV
Hwang YJ, Lesko CR, Brown TT, Alexander GC, Althoff KN, Zalla LC, Pytell JD, Falade-Nwulia O, Tseng E, Moore RD, Marconi VC, Koethe JR, Silverberg MJ, Horberg MA, Lang R, Sterling TR, Fojo AT, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS.   +17 more
europepmc   +1 more source

Molecular mechanisms of protease precursor autoprocessing of RNA viruses: a comprehensive review. [PDF]

Virol J
Mótyán JA, Golda M, Mahdi M, Nashed NT, Louis JM, Tőzsér J.   +5 more
europepmc   +1 more source

Genetic diversity and drug resistance mutations of HIV-1 in Ghana: a systematic review of two decades. [PDF]

BMC Infect Dis
Appiah P, Adusei-Poku M, Obeng BM, Osei-Yeboah R, Gbassana G, Agyemang S, Mac-Ankrah L, Jamfaru I, Seshie M, Sraku IK, Ankamah S, Duedu KO, Sagoe KWC.   +12 more
europepmc   +1 more source

Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Brief Report: Is Gestational Exposure to HIV and Protease Inhibitors Associated With Timing of Pubertal Onset? [PDF]

J Acquir Immune Defic Syndr
Serghides L, Lee J, Jacobson DL, Geffner ME, DiMeglio LA, McFarland EJ, Powis KM, Williams PL, Jao J, Pediatric HIV/AIDS Cohort Study.   +9 more
europepmc   +1 more source

A Double-Edged Sword: Extracellular Serine Proteases as Facilitators of Infection and Mediators of Immunity. [PDF]

Molecules
Shagirova A, Allayarova M, Makhanova A, Bekturgan A, Burster T.   +4 more
europepmc   +1 more source

Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2' ligands with potent activity against drug-resistant variants. [PDF]

Eur J Med Chem
Kaur J, Spielvogel E, Nageswara Rao D, Rusere LN, Shaqra AM, Lockbaum GJ, Maryam A, Yilmaz NK, Swanstrom R, Schiffer CA, Ali A.   +10 more
europepmc   +1 more source

Modeling NRTIs and PIs class drug therapy on the dynamics of HIV infection with real patient data analysis and optimized control strategy. [PDF]

Sci Rep
Sardar P, Ranjit B, Biswas S, Boulaaras SM, Allali K, Pal B, Das KP.   +6 more
europepmc   +1 more source

Virtual Screening of FDA-Approved Compounds: Exploring New Alternatives for HIV Treatment. [PDF]

ACS Omega
Martinez DP, Kremer FS.
europepmc   +1 more source

Highly Potent Phosphinic HIV‑1 Protease Inhibitors: Synthesis, In Vitro Evaluation, and Docking Studies. [PDF]

ACS Omega
Hayat K, Qiu D, Wang Y, Imbenzi PS, Khan FI, Matziari M.   +5 more
europepmc   +1 more source